Trifecta GT

Surgical Valve
Replacement the
Gold Standard for
Aortic Valve Stenosis1

The Trifecta valve with Glide Technology (GT) is intended as a replacement for a diseased, damaged, or malfunctioning native or prosthetic aortic heart valve.

Surgical aortic valve replacement (SAVR)—for example, with the Trifecta valve—is the gold standard for the treatment of aortic stenosis.1

Bleak Prognosis Without Treatment

If symptomatic patients with aortic valve stenosis—who are already on medical therapy—do not undergo aortic valve replacement, mortality rates are approximately 25% at 1 year and 50% at 2 years. Aortic valve replacement is the only definitive treatment for such patients.2

Priorities When Selecting SAVR

When selecting a SAVR valve, physicians are encouraged to consider:

  • Hemodynamic performance
  • Rate of prosthetic-patient mismatch

AP2947045-WBO Rev. A

References
  1. Bonow RO, et al. Management strategies and future challenges for aortic valve disease. Lancet. 2016;387:1312–1323.
  2. Ren X. Aortic stenosis. MedScape. emedicine.medscape.com/article/150638-overview. Published March 23, 2017.
     

This site uses cookies to improve your experience.

To find out more please read our Privacy and Cookies policy.

Ok

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.